Home・Lista de Ações・Xencor Inc

Xencor Inc

Fechado

SetorSaúde

19.36 -0.62

Comprar Vender

Visão Geral

Variação de preço das ações

24h

Atual

Mín

18.87

Máximo

19.85

Indicadores-chave
By Trading Economics
Rendimento	-214M -129M
Vendas	-24M 4.5M
EPS	-1.71
Margem de lucro	-2,854.65
Funcionários	260
EBITDA	-127M -121M

Recomendações
By TipRanks
Recomendações	Compra Forte
Previsão para 12 meses	+23.4% upside

Dividendos
By Acuity
Próximos Ganhos	4 de ago. de 2026

Estatísticas de Mercado
By TradingEconomics
Capitalização de Mercado	404M 1.4B
Abertura anterior	19.98
Fecho anterior	19.36

Sentimento de Notícias

By Acuity

50%

163 / 340 Ranking em Healthcare

Xencor Inc Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

24 de jul. de 2026, 19:11 UTC

Xencor Inc shares are lower in Friday's session, reflecting broader market trends. No specific news was identified to explain the price movement.

22 de jul. de 2026, 20:06 UTC

Xencor Inc shares are lower today, retracing from an earlier peak. Broader market sentiment is affected by uncertainty ahead of the Federal Reserve meeting.

21 de jul. de 2026, 19:02 UTC

Social Media

Xencor Inc. shares reached a new 52-week high, driven by developments in RCC related to ENPP3 and immuno-oncology efforts involving TL1A.

20 de jul. de 2026, 19:41 UTC

Social Media

Xencor Inc's shares are higher as clinical results are accepted for presentation at the ESMO conference, with a Phase 3 trial planned for 2027.

Comparação entre Pares

Variação de preço

Xencor Inc Previsão

Preço-alvo

By TipRanks

23.4% parte superior

Previsão para 12 meses

Média 24.1 USD 23.4%

Máximo 38 USD

Mínimo 13 USD

Com base em 11 analistas de Wall Street que oferecem metas de preço de 12 meses para Xencor Inc - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Compra Forte

11 ratings

Comprar

Manter

Vender

Com base em 11 analistas que deram avaliações de ações para Xencor Inc - Dist nos últimos 3 meses.

Sentimento

By Acuity

163 / 340 Ranking em Saúde

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

Sobre Xencor Inc

Xencor, Inc. is a clinical-stage biopharmaceutical company that is focused on discovering and developing engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The Company uses its engineering capabilities to enable its understanding of protein structure and interactions to design XmAb technologies and develop candidates with properties. Its antibody design is focused on the segment of antibodies that interact with target antigens. It is focused on the Fc domain, which is the part of an antibody that interacts with various segments of the immune system and controls antibody structure. The Fc domain is constant and interchangeable among antibodies, and its engineered Fc domains are the XmAb technology, which can be readily substituted for natural Fc domains. Its drug candidates include Plamotamab, XmAb717, Vibecotamab, Tidutamab, XmAb841, XmAb104, XmAb306, XmAb104, XmAb564 and XmAb698.